Guselkumab Shows Long-Term Efficacy in Ulcerative Colitis Treatment
Results from the phase 3 QUASAR trials show that guselkumab offers effective and safe induction and maintenance therapy for moderate-to-severe ulcerative colitis, with nearly 50% of patients achieving clinical remission after one year.